SCHEMBL1543041

SCHEMBL1543041

COc1c(CCc2ccc(NS(C)(=O)=O)nc2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.78
PCSK9 Q8NBP7 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PIK3CG P48736 1/20 0.33
CRBN Q96SW2 1/20 0.32
FYN P06241 1/20 0.31
TGFBR1 P36897 1/20 0.31
ACVR1 Q04771 1/20 0.31
BRD4 O60885 1/20 0.31
CDK2 P24941 1/20 0.31
CDK9 P50750 1/20 0.31
IRAK1 P51617 1/20 0.31
PTK2 Q05397 1/20 0.31
SRPK1 Q96SB4 1/20 0.31
SLK Q9H2G2 1/20 0.31
MAP4K5 Q9Y4K4 1/20 0.31
LYN P07948 1/20 0.31
MAPK9 P45984 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542490 0.91 CYP3A4 (0.77) CYP3A4PCSK9PIK3CDPIK3CAPIK3CB
SCHEMBL1542870 0.89 CYP3A4 (0.69) CYP3A4PCSK9PIK3CDPIK3CAPIK3CB
SCHEMBL1542581 0.88 CYP3A4 (1.00) CYP3A4CRBNBRD4
SCHEMBL1542679 0.87 CYP3A4 (0.71) CYP3A4CRBNALPL
SCHEMBL1542721 0.85 CYP3A4 (0.78) CYP3A4CRBNCDK2CDK9IRAK1
SCHEMBL2128400 0.84 CYP3A4 (0.84) CYP3A4CRBNFYNTGFBR1ACVR1
SCHEMBL1542612 0.84 CYP3A4 (0.77) CYP3A4
SCHEMBL1542813 0.84 CYP3A4 (0.77) CYP3A4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL1542447 0.81 CYP3A4 (0.78) CYP3A4PCSK9PIK3CDPIK3CAPIK3CB
SCHEMBL1764947 0.81 CYP3A4 (0.78) CYP3A4PCSK9PIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885PCSK9 2433/4885PIK3CD 1964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.